Loading...

Ocumension Therapeutics

1477.HKHKSE
Healthcare
Biotechnology
HK$9.47
HK$-0.97(-9.29%)

Ocumension Therapeutics 1477.HK Peers

See (1477.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
1477.HKHK$9.47-9.29%8.7B-24.60-HK$0.43N/A
1801.HKHK$79.30+1.15%131B-1321.67-HK$0.06N/A
2269.HKHK$25.65+0.00%104.4B30.18HK$0.85N/A
1177.HKHK$5.33+0.57%94.1B47.82HK$0.11+1.31%
9926.HKHK$92.80+0.92%83.2B-142.77-HK$0.65N/A
1530.HKHK$24.25+6.83%55.8B25.43HK$0.93+1.03%
3759.HKHK$16.68+0.60%42.9B14.50HK$1.15N/A
9995.HKHK$55.25+1.47%37.8B-18.54-HK$2.98N/A
1877.HKHK$21.50+3.61%35.1B-15.14-HK$1.42N/A
6821.HKHK$78.20-0.64%34.5B25.39HK$3.08+1.54%
Showing 1 to 10 of 56 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

1477.HK vs 1801.HK Comparison

1477.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 1477.HK stands at 8.7B. In comparison, 1801.HK has a market cap of 131B. Regarding current trading prices, 1477.HK is priced at HK$9.47, while 1801.HK trades at HK$79.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

1477.HK currently has a P/E ratio of -24.60, whereas 1801.HK's P/E ratio is -1321.67. In terms of profitability, 1477.HK's ROE is -0.08%, compared to 1801.HK's ROE of -0.01%. Regarding short-term risk, 1477.HK is more volatile compared to 1801.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 1477.HK.

Stock Price Comparison

Loading...

Frequently Asked Questions

;